CID-078

Product Description

CID-078 is an orally bioavailable macrocycle with dual cyclin A and B inhibitory activity that drives synthetic lethality in multiple tumor types. In biochemical and cellular studies, CID-078 has been shown to potently and selectively disrupt the protein-protein interaction between Cyclins A and B and their key substrates, including E2F (a substrate of Cyclin A) and Myt1 (a substrate of Cyclin B). Preclinical studies have demonstrated the ability of CID-078 to cause pronounced tumor regression in multiple xenograft models. Circle Pharma plans to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for CID-078 and initiate clinical development in 2024. (Sourced from: https://www.benzinga.com/pressreleases/23/07/b33281591/circle-pharma-achieves-major-milestone-with-the-selection-of-a-clinical-development-candidate-dire)

Mechanisms of Action: CCNA1 Inhibitor, CCNB1

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Orphan Drug - Small Cell Lung Cancer *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Circle Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None